Sun Pharma Advanced Research Company Limited Share Price and Company Fundamentals



Price
₹204.35
Change
1.500 (0.739%)
52 week
170.45 - 349.0

Last traded: Today at 9:59 AM

Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops new chemical and biological entities, and reformulated products with a therapeutic focus on oncology, neurodegeneration, ophthalmology, and dermatology. The company offers Elepsia, a formulation of levetiracetam that is an anti-epileptic agent to treat epilepsy disorder; and Xelpros, a latanoprost ophthalmic emulsion for the treatment of open-angle glaucoma or ocular hypertension. In addition, it is developing SDN-037, a formulation of difluprednate for the treatment of inflammation and pain associated with ocular surgery that is in phase 3 clinical trial; PDP-716 to treat glaucoma, which is in phase 3 clinical trial; phenobarbital sodium for the treatment of neonatal seizures; Vodobatinib (SCO-088) for the treatment of resistant chronic myelogenous leukemia that has completed a part A of the Phase 1 study; Vodobatinib (SCC-138), which is in phase 2 clinical trial to treat Parkinson's disease; SCD-044 for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial; and SCO-120 for the treatment of hormone receptor-positive, human epidermal receptor 2 negative, and metastatic breast cancer, which is in phase 1 clinical trial. Sun Pharma Advanced Research Company Limited has a collaboration agreement with Bioprojet SCR to develop an S1P receptor 1 agonist for autoimmune disorders; and HitGen Ltd. to identify small molecule leads for targets of interest. The company was incorporated in 2006 and is based in Mumbai, India. Sun Pharma Advanced Research Company Limited is a subsidiary of Shanghvi Finance Private Limited

Key Metrics

PE ratio

-

PB ratio

178.55

Dividend yield

0.00%

Beta

1.04

Market cap

-

Enterprise value

-

Company profile

Industry / SectorDrug Manufacturers—Specialty & Generic / Healthcare
Websitehttps://www.sparc.life
Mailing address17-B, Mahal Industrial Estate Off Mahakali Caves Road Andheri (East) Mumbai 400093 India
Phone / Fax91 22 6645 5645 / 91 22 6645 5685

Dividends

Dividend yield

0.00%

Dividend amount

₹0.00

Payout ratio

0.00%

Sun Pharma Advanced Research Company Limited paid ₹0.00 dividend and the ex-dividend date was .The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.SPARC dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.

SPARC's forward dividend amount is ₹ and the forward dividend yield is . A forward dividend yield is the percentage of a company's current stock price that it expects to pay out as dividends over a certain time period, generally 12 months. Forward dividend yields are generally used in circumstances where the yield is predictable based on past instances. If not, trailing yields, which indicate the same value over the previous 12 months, are used.

Company Executives

As of Jul 2022, following are the company executives and directors listed on Sun Pharma Advanced Research Company Limited.

NameTitleAgeTotal Pay
Mr. Anilkumar RaghavanChief Exec. Officer52
Mr. Chetan M. RajparaChief Financial Officer15.14M
Mr. Siu-Long YaoExec. VP Clinical Devel. & Operations
Mr. Jaydeep IssraniSr. Gen. Mang. of Bus. Devel., Corp. Communication & Investor Relations
Mr. Dinesh Poosraj LahotiCompany Sec. & Compliance Officer
Ms. Shanta GuptaChief Human Resource Officer
Dr. Subhas BhowmickSr. VP65
Dr. Trinadha Rao ChitturiSr. VP of R&D62
Dr. Nitin DharmadhikariExec. VP and Head Operational Excellence & COE's59
Dr. Nitin K. Damle Ph.D.Sr. VP & Chief Innovation Officer

Profitability and management effectiveness

Profit margin

-148.20%

Operating margin

-143.47%

Return on assets

-48.28%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Sun Pharma Advanced Research Company Limited is and its enterprise value is .

The SPARC's stocks Beta value is 1.04 making it 4% more volatile compared to NSE market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Sun Pharma Advanced Research Company Limited (NSE:SPARC) Frequently Asked Questions

1. What is Sun Pharma Advanced Research Company Limited's Stock Symbol?

Sun Pharma Advanced Research Company Limited trades on NSE under the ticker symbol "SPARC".

2. What is Sun Pharma Advanced Research Company Limited's stock price today?

One share of SPARC stock can currently be purchased for approximately ₹204.35.

3. How can I contact Sun Pharma Advanced Research Company Limited?

Sun Pharma Advanced Research Company Limited's mailing address is 17-B, Mahal Industrial Estate Off Mahakali Caves Road Andheri (East) Mumbai 400093 India. The company can be reached via phone at 91 22 6645 5645.

4. What is Sun Pharma Advanced Research Company Limited's official website?

The official website of Sun Pharma Advanced Research Company Limited is https://www.sparc.life.